The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA grants lisocabtagene maraleucel priority review for R/R CLL or SLL
On November 9, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted lisocabtagene maraleucel, a chimeric antigen receptor T-cell therapy, priority review for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). This decision is based on promising results from the TRANSCEND CLL 004 (NCT03331198) trial.1
TRANSCEND CLL 004
TRANSCEND CLL 004 is a phase I/II open-label study evaluating lisocabtagene maraleucel in patients with relapsed/refractory CLL/SLL.1 The Lymphoma Hub previously reported the promising initial results at a median follow-up of 21 months which are summarized in Figure 1.2
Figure 1. Lisocabtagene maraleucel efficacy in patients with R/R CLL/SLL*
CRi, complete response with incomplete hematologic recovery; ORR, overall response rate; uMRD, undetected minimal residual disease.
*Adapted from Siddiqi, et al.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content